Unlock Insights from DIA 2025
Explore how oncology breakthroughs are transforming clinical trial design and research in neurology, infectious disease, and rare diseases.
At DIA 2025, MMS thought leaders Margaret Studzinska and Ritchie Patton presented their latest research during Poster Session II. Now, you can access the full poster and learn how adaptive trial design methodologies, biomarker-driven strategies, and accelerated development pathways pioneered in oncology are being applied to complex trials and research in other therapeutic areas.
Leveraging Oncology Innovations for Advancements in Neurology, Infectious Disease, Rare Disease Clinical Trials and Research
What you’ll learn:
- How oncology trial strategies are being adapted across therapeutic areas
- Practical applications of biomarker-driven strategies, surrogate endpoints, and adaptive trial methodologies
- Opportunities to improve trial efficiency and accelerate the development of targeted therapies
Click below to view the full poster and explore key insights from our experts.
Meet the Authors:
Senior Director, Regulatory and Medical Writing
Margaret Studzinska, MBA is a Senior Director, Regulatory and Medical Writing, with over 15 years of experience in clinical research and regulatory and medical writing. She has supported multiple regulatory submissions to global health authorities such as FDA (US) and EMA (EU). Her regulatory document expertise includes writing clinical, non-clinical, and CMC documents. Her key responsibilities include diverse workforce management, providing technical guidance to the team, and training writers on various regulatory documents.
Associate Director, Regulatory Strategy
Ritchie Patton is the Associate Director of Regulatory Strategy at MMS Holdings, where he leads cross-functional regulatory initiatives that support pharmaceutical and biotech clients through complex drug development pathways. With a strong foundation in regulatory science and a strategic mindset, Ritchie is known for his ability to translate evolving regulatory frameworks into actionable strategies, particularly in areas involving FDA guidance interpretation, AI implementation, and risk mitigation. His leadership ensures that client programs are not only compliant but also positioned for long-term success in a competitive regulatory landscape.